Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Research analysts at Leerink Partnrs lowered their Q4 2024 earnings per share estimates for Laboratory Co. of Amer ...

Align Technology (NASDAQ:ALGN) been upgraded to outperform from market perform by Leerink Partners. Calling Align ...

Truist has recently initiated Solid Biosciences Inc (SLDB) stock to Buy rating, as announced on Today, according to Finviz. Earlier, on December 13, 2024, Wedbush had initiated the stock to Outperform ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...

Leerink analyst Daina Graybosch downgraded Lava Therapeutics (LVTX) to Market Perform from Outperform with a price target of $2, down from $11, following the company’s discontinuation of LAVA ...

Leerink analyst Daniel Clark initiated coverage of Zoetis (ZTS) with an Outperform rating and $215 price target The firm notes . Zoetis has been one of the best performing names in animal health ...

Leerink upgraded Align Technology (ALGN) to Outperform from Market Perform with a price target of $280, up from $235. For what remains a clear ...